Cationic nanodrug, preparation method therefor, and drug-loaded implantable medical device
AssigneeShanghai Microport Medical (Group) Co., Ltd.
InventorsMeng Li, Yufu Wang, Junfei Li
Life of this patent
Estimating the term…
Abstract
Disclosed are a cationic nanodrug, a preparation method therefor, and a drug-loaded implantable medical device, wherein the cationic nanodrug comprises a vector and a drug loaded on the vector, and the vector comprises one or more of a cationic amphipathic compound and a cationic modifier; the cationic amphipathic compound is a cationic amphipathic compound containing amino and/or acyl; and the cationic modifier is a cationic modifier containing amino and/or acyl. The cationic nanodrug greatly improves the uptake of a drug by cells and has a good slow-release effect.
Claims8
A method of preparing a cationic nanodrug, comprising the steps of:
- providing a first liquid stream;
- providing a second liquid stream;
- and
- performing an instantaneous nanoprecipitation process in which the first and second liquid streams collide with each other to create a vortex stream where the two streams are mixed to form a nanosuspension, and obtaining the cationic nanodrug through collecting and dialyzing the nanosuspension,
- wherein a drug is dissolved in at least one of the first and second liquid streams and a a carrier is dissolved in the other one of the first and second liquid streams, wherein the drug is an antiproliferative drug selected from one or more of the group consisting of paclitaxel, sirolimus and derivatives of sirolimus, wherein one of the first and second liquid streams contains a water-soluble organic phase, and the other one of the first and second liquid streams contains an aqueous phase, wherein the carrier comprises one or more of a cationic amphiphilic compound and a cationic modifier, the cationic amphiphilic compound being an amino- and/or acyl-containing cationic amphiphilic compound, the cationic modifier being an amino- and/or acyl-containing cationic modifier;
- wherein the cationic nanodrug has a particle size ranging from 50 nm to 250 nm;
- wherein the particle size is uniform;
- wherein a surface potential of the cationic nanodrug is adjusted by changing contents of the cationic amphiphilic compound and the cationic modifier, and wherein the cationic nanodrug has a surface charge of 10-60 mV.
Dependencies are inferred from the claim text.